Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Pancreatic Neoplasms 8Unspecified Adult Solid Tumor, Protocol Specific 1Resectable Pancreatic Carcinoma 1Resectable Pancreatic Cancer 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Breast Neoplasms 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1Adenocarcinoma of the Pancreas 1Adenocarcinoma 1

Interventions

Radiosurgery 79Capecitabine 77Oxaliplatin 74Fluorouracil 69Bevacizumab 69Gemcitabine 67Leucovorin 61pembrolizumab 53Nivolumab 53Paclitaxel 48Irinotecan 47Radiotherapy 45Cisplatin 44Everolimus 38Magnetic Resonance Spectroscopy 36Drug Therapy 36Docetaxel 36Cyclophosphamide 35Cetuximab 35Ipilimumab 32Carboplatin 32Trastuzumab 31Sunitinib 30Sorafenib 26Erlotinib Hydrochloride 25Doxorubicin 23Surveys and Questionnaires 20Surgical Procedures, Operative 20Specimen Handling 20Biopsy 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoplasm Metastasis × paricalcitol × Clear all
NCT00634582 2018-07-06

Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases

Wake Forest University Health Sciences

Phase 2 Terminated
2 enrolled 6 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡